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Abstract
Background and objectives
Statins showed mixed results in heart failure (HF) patients. The benefits in major HF out-
comes, including all-cause mortality and sudden cardiac death (SCD), have always been
discordant across systematic reviews and meta-analyses. We intended to systematically
identify and appraise the available evidence that evaluated the effectiveness of statins in
clinical outcomes for HF patients.
Design
Systematic review and meta-analysis
Data sources
We searched, until April 28, 2016: Medline, Embase, ISI Web of Science and EBM reviews
(Cochrane DSR, ACP journal club, DARE, CCTR, CMR, HTA, and NHSEED), checked clini-
caltrials.gov for ongoing trials and manually searched references of included studies.
Eligibility criteria for selecting studies
We identified 24 randomized clinical trials that evaluated the efficacy of statins for HF patients.
All randomized clinical trials were assessed for risk of bias and pooled together in a meta-anal-
ysis. Pre-specified outcomes were sudden cardiac death, all-cause mortality, and hospitaliza-
tion for worsening heart failure.
Results
Statins did not reduce sudden cardiac death (SCD) events in HF patients [relative risk (RR)
0.92, 95% confidence interval (CI) 0.70 to 1.21], all-cause mortality [RR 0.88, 95% CI 0.75
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to 1.02] but significantly reduced hospitalization for worsening heart failure (HWHF) although
modestly [RR 0.79, 95% CI 0.66 to 0.94]. Nevertheless, estimated predictive intervals were
insignificant in SCD, all-cause mortality and HWHF [RR, 0.54 to 1.63, 0.64 to 1.19, and 0.54
to 1.15], respectively. An important finding was the possible presence of publication bias,
small-study effects and heterogeneity of the trials conducted in HF patients.
Conclusions
Statins do not reduce sudden cardiac death, all-cause mortality, but may slightly decrease
hospitalization for worsening heart failure in HF patients. The evaluation of the risk of biases
suggested moderate quality of the published results. Until new evidence is available, this
study supports the 2013 ACCF/AHA guidelines to not systematically prescribe statins in
“only” HF patients, which should help avoid unnecessary polypharmacy.
Introduction
Heart failure (HF) patients are likely to take more than one drug and tend toward polypharmacy.
Guideline-directed medical therapy includes angiotensin converting enzyme inhibitors, beta-
blockers, aldosterone antagonists as well as implantable cardioverter defibrillators, which all have
reported a reduction in mortality and morbidity in heart failure patients [1–4]. Though, such
benefits are still insufficient to the current management need as almost half of HF patients die
within 5 years after initial diagnosis and half of the mortality is attributed to sudden cardiac death
(SCD) [5,6]. More potential benefits are hypothesized with statin treatment but current ACCF/
AHA guidelines do not recommend statins for only HF diagnosis [7]. However, 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-Co A) reductase inhibitors or simply statins are still widely
prescribed for HF patients [8].
Several studies [9–11] evaluated the effects of statin on sudden cardiac death prevention but
with a variety of population characteristics which made the result difficult to apply for HF patients.
Oppositely, two large randomized clinical trials (RCTs) [12,13] in heart failure reported no reduc-
tion of all-cause mortality and SCD events by statins. Moreover, studies often evaluated surrogate
endpoints or biomarkers other than important clinical endpoints such as mortality and that might
have exaggerated the expected benefits of statins[14].
A systematic review [15], published in 2006, stressed on the importance of this research
question and pointed out the conflicting and unclear evidence. CORONA [13] and GISSI-HF
[12] (unpublished at that time) was expected to resolve the issue. In the contrary, both studies,
after publication, raised controversial statements and debates. The morbidity and mortality
rate among HF patients is considerably high and an emphasis on effective prevention strategies
would lead to a significant reduction of such events. Similarly, HF patients have a reduced lon-
gevity thus the need for providing clinicians and health care actors an optimal evidence-based
strategy is of vital importance.
Nevertheless, current trials, systematic reviews and meta-analyses [16–24] for statins have
shown mixed results for major HF outcomes. Positive studies were not immune to bias, serious
limitations or indirectness. Therefore, we intended to evaluate and update the quality of evi-
dence of statins efficacy to reduce SCD, mortality or hospitalization for worsening heart failure
(HWHF) by means of a systematic review and a meta-analysis with a careful consideration of
potential biases in published studies.
Statins for sudden cardiac death prevention in heart failure
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Methods
Study search strategy
We searched Medline (1946 to April 28, 2016), Embase (1974 to April 28, 2016), EBM reviews
(Cochrane DSR, ACP journal club, DARE, CCTR, CMR, HTA, and NHSEED) (to April 28,
2016), and ISI web of science (‘‘All years” to April 28, 2016) via an Ovid online interface and iden-
tified systematic reviews and meta-analyses via a search strategy accessible on S1 File. In a first
step, we used a filter [25,26] to search for systematic reviews and meta-analyses and initially
excluded individual clinical trials for the purpose of our study. In a second step, we searched for
primary studies and included randomized clinical trials evaluating statins in heart failure patients.
In Medline and Embase, we combined medical subject heading terms (MeSH and EMTREE
respectively), text words as well as a truncation when appropriate. The method included a combi-
nation of a disease (i.e., heart failure), an intervention (i.e., statins) as well as the aforementioned
filter. Also, we added an outcome (i.e., sudden cardiac death and/or mortality) to limit the research
output. No language restrictions were applied and a bimonthly alert was set up for an automatic
update during the study. We also checked the references of included studies for potential addi-
tional studies, searched clinicaltrials.gov and tried to contact authors for additional or missing
data. Fig 1 shows the search strategy results according to the PRISMA guidelines (see also S2 File).
Selection criteria and data abstraction
We included randomized clinical trials (RCTs) that evaluated statins efficacy in heart failure
patients and contained at least one outcome of interest. No exclusion was based on treatment
duration or follow-up period, language or intention-to-treat analysis. Risk of bias was deter-
mined by the Cochrane risk bias assessment tool [27]. Two reviewers (MA&HHL) indepen-
dently collected data and were checked by a third reviewer (MF) while discrepancies were
resolved via discussion and consensus. Abstracted data included eligibility criteria, baseline
characteristics, study design (including treatment and control arms), follow-up duration, and
Fig 1. Flow chart for search result.
doi:10.1371/journal.pone.0171168.g001
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outcomes. Pre-specified outcomes of interest included sudden cardiac death (SCD), all-cause
mortality and hospitalization for worsening heart failure (HWHF) and were analyzed accord-
ing to an intention-to-treat principle when possible.
Statistical analysis
We pooled the data in a meta-analysis, using random-effects and fixed-effects model with Man-
tel-Haenszel methods that are preferable to inverse variance methods in case of few events [27].
Sensitivity and subgroup analyses were done to verify the extent to which different hypotheses
might change our confidence in the result. The effect size was relative risk or risk ratio (RR),
confidence intervals (CIs) of 95% was given when applicable and a significance level was deter-
mined at two-sided alpha less than 5%. We reported both fixed-effect and random-effects mod-
els for the meta-analysis and used risk ratios (RR) as the summary effect estimate that may give
better interpretation as the outcome is hospitalization or death events, termed bad outcome.
We calculated the absolute effect or the absolute risk reduction (ARR) for SCD, all-cause mor-
tality and HWHF with an assumed control risk (ACR) of 0.11, 0.27 and 0.38 respectively. To
check the validity of choosing the summary statistic, odds ratio (OR) was used instead of RR in
a sensitivity analysis. The 95% prediction interval, an interval that estimate a treatment effect of
a new or future trial within which we are confident it lies, was given when a random-effects
model is used. Also, we rated the quality of the evidence using a summary of findings table from
the GRADE approach [28]. We computed the sample size required to reach a statistical signifi-
cance according to the observed differences between the groups of statin and placebo or control
for all outcomes [α = 5% and power (1- β) = 0.80] and intended to stratify the studies according
to follow-up and sample size in subgroup and sensitivity analyses. Heterogeneity was measured
by I-squared (I2, variation in RR/OR attributable to heterogeneity) and Tau-squared (Tau2, esti-
mate of between-study variance). We noticed that the follow-up period differed largely from
one study to another from one month [29,30] to more than 30 months [12,13,31]. Therefore,
studies were grouped according to follow-up as a potential determinant of any heterogeneity
among studies. Data was analyzed with STATA version 14.1 (StataCorp LP, Texas), RevMan
(version 5.3) and GradePro (version 3.6.1).
Results
Study selection
Electronic databases and manual searches resulted in 1335 studies after removal of duplicates.
After screening of titles and abstracts and examination of selected full-texts, we ended up with
17 systematic reviews/meta-analyses [9,11,18–24,32–39] and 24 randomized controlled trials
(RCTs) [12,13,40–51] [29,31,52] [30,53–58] (Fig 1).
Study and baseline patient characteristics
As shown in Tables 1 and 2, we identified 24 RCTs of statins in heart failure (HF) patients for
inclusion in this meta-analysis, which enrolled a total of 11,463 patients. The mean and the
median of follow-up duration were 11.5 and 6 months respectively. The studies included in
majority male participants (ratio ranged from 54% to 100%) with an average age of 60 years.
The mean age of the three biggest studies (CORONA [13], GISSI-HF [12] and Takano H. et al.
(PEARL) [31]) was 68 years. All studies included HF patients with New York Heart Association
classification (NYHA) ranging from I-IV and at least 9 studies included stable HF patients.
Seven studies included non-ischaemic HF patients, 4 studies exclusively ischaemic, 12 included
both types and one unknown. All patients in included studies had an ejection fraction less than
Statins for sudden cardiac death prevention in heart failure
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45% and no one included HF with a preserved ejection fraction (HFpEF). Baseline mean lipid
levels were relatively similar from one study to another with mean low-density lipoprotein
Table 1. Randomized trials of statins in heart failure patients.
Trial [Reference] Publication
Year
Number of patients
(statin/comparator)
Name of
drug
Comparator Mean baseline
Lipids
Primary Endpoint Dosage (mg/
day)
Follow-up
(months)
AbdulHul E. et al.
[40]
2012 56(28/28) Atorvastatin No statin LDL-c = 2.73
mmol/L
Biomarkers, BNP 40 6
Bielecka-D. et al.
[41]
2009 68(41/27) Atorvastatin No statin LDL-c = 3.15
mmol/L
Factors affect
HWHF/mortality
10–40 6
Bleske BE. et al.
[42]
2006 18(9/9)* Atorvastatin Placebo LDL-c = 2.84
mmol/L
Surrogate markers in
NICM
80 3
CORONA [13] 2007 5011(2514/2497) Rosuvastatin Placebo LDL-c = 3.55
mmol/L
HWHF/SCD/mortality 10 32.8
Erbs S.et al. [43] 2011 42(22/20) Rosuvastatin Placebo LDL-c  3.78
mmol/L
Pleiotropic effects 40 24
Gissi-HF
Investigators [12]
2008 4574(2285/2289) Rosuvastatin Placebo NR HWHF/SCD/mortality 10 46.8
Hammad A. et al.
[44]
2005 23(13/10) Atorvastatin Placebo TC  3.5
mmol/L
Autonomic nervous
system
40 3
Hong et al.[58] 2005 202(106/96) Simvastatin No statin LDL-c  3.62
mmol/L
PCI rate, restenosis,
mortality
40 12
Horwich TB. et al.
[45]
2011 26(14/12) Atorvastatin Placebo LDL-c  2.79
mmol/L
Sympathetic nervous
system
10 3
Krum et al. [46] 2007 86(40/45) Rosuvastatin Placebo NR Ventricular
remodeling
10–40 6
Laufs U. et al.[47] 2004 15(8/7) Cerivastatin Placebo LDL-c  3.46
mmol/L
Pleiotropic effects 0.4 5
Liu M. et al. [48] 2009 64(32/32) Atorvastatin Placebo LDL-c 
3.03mmol/L
Inflammation 10 3
Mozaffarian D.et al.
[49]
2005 22(12/10) Atorvastain Placebo LDL-c = 3.33
mmol/L
Inflammation 10 2
Node K. et al. [50] 2003 51(23/25) Simvastatin Placebo LDL-c  3.85
mmol/L
Cardiac function 5–10 3.5
Sola S. et al. [51] 2006 108(46/43) Atorvastatin Placebo LDL-c  3.12
mmol/L
Inflammation 20 12
Strey CH. et al. [52] 2006 23(11/12)* Atorvastatin Placebo LDL-c  3.56
mmol/L
Endothelial function 40 1.5
Takano H. et al.[31] 2013 577(288/286) Pitavastatin No statin LDL-c  3.24
mmol/L
Mortality /HWHF/
stroke
2 35.5
Tousoulis D.et al.
[29]
2005 38(19/19) Atorvastatin No statin TC  4.83
mmol/L
Inflammation 10 1
Tousoulis D.et al.
[30]
2004 38(14/12) Atorvastatin No statin TC  5.04
mmol/L
Inflammation 10 1
Vrtovec B. et al.
[53]
2005 80(40/40) Atorvastatin No statin TC  5.07
mmol/L
HRV/ QTV/ QTc 10 3
Vrtovec B. et al.
[54]
2008 110(55/55) Atorvastatin No statin LDL-c = 2.45
mmol/L
SCD 10 12
Wojnicz R. et al.
[55]
2006 74(36/38) Atorvastatin No statin LDL-c  4.18
mmol/L
Inflammation 40 6
Xie RQ. et al.[56] 2008 119(78/41) Atorvastatin Statin/no
statin
LDL-c  3.64
mmol/L
Cardiac function 10–20 12
Yamada T. et al.
[57]
2007 38(19/19) Atorvastatin No statin LDL-c  3.02
mmol/L
Cardiac function 10 31
BNP: B-type natriuretic peptide; HRV: heart rate variability; QTV: QT variability; QTc: QTc interval; HWHF: Hospitalization for worsening heart failure; LDL-
c: lowdensity lipoprotein cholesterol; NICM: Non-Ischaemic Cardiomyopathy; PCI: percutaneous coronary intervention; SCD: sudden cardiac death; TC:
total cholesterol; NR: not reported;: approximately.
* Estimated values
doi:10.1371/journal.pone.0171168.t001
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cholesterol (LDL-c) of 3.3 for 19 studies and mean total cholesterol (TC) of 5.19 for 3 studies
and unknown for 2 studies. Only 5 studies[13] [12] [31] [58] [54] had a mortality endpoint
while others evaluated surrogate endpoints and biomarkers. Statins were compared to placebo
in 13 studies and to no statin in 10 studies; one study compared two different doses of statins to
a no statin group[56].
Risk of bias and quality of studies
We assessed studies’ risk of bias by means of the Cochrane bias tool[27]. We noticed that the
intention-to-treat principle was not followed in all trials, among which 10 had either high or
unclear risk (Fig 2(B)). Most of the included trials had unclear risk towards blinding of investiga-
tors or outcome assessors. Overall, the studies fluctuated from high to moderate/low level of qual-
ity. Fig 2 (A) shows the summary of bias risk assessment in percentages and for each included
trial. We also rated each outcome (SCD, All-cause mortality and hospitalization for worsening
heart failure (HWHF)) according to the GRADE approach (Fig 3). Studies were evaluated per
outcome for any bias, inconsistency, indirectness, imprecision or publication bias. The latter was
Table 2. Patient characteristics in randomized trials of statins in heart failure patients.
Trial [Reference] Mean age
(Years)
Male
(%)
Inclusion criteria Population (Ischaemic or non-
ischaemic, %)
Mean LVEF
(%)
NYHA
AbdulHul E. et al.[40] 72 68 Mild-moderate HF, LVEF 45% Ischaemic, 64 35 II-III
Bielecka-D. et al.[41] 57 85 Stable HF with DC NR 29 I-III
Bleske BE. et al.[42] 56 60 CHF due to NICM, LVEF<40% Non-ischaemic 25 I-III
CORONA [13] 73 76 Ischaemic HF, age 60,
LVEF < 40%
Ischaemic,100 31 II-IV
Erbs S.et al. [43] 62 76 CHF—Ischaemic HF or DC Ischaemic,28 30 II-III
Gissi-HF Investigators
[12]
68 77 CHF, No LVEF restriction Ischaemic,40 33 II-IV
Hammad A. et al. [44] 67 86 Stable systolic HF Ischaemic, 57 31 II-III
Hong et al.[58] 61 72 Patients underwent PCI for AMI Ischaemic, 100 31 II-IV
Horwich TB. et al. [45] 48 62 Symptomatic HF, LVEF 35% Non-ischaemic 26 I-III
Krum et al. [46] 62 80 NYHA II-IV, LVEF 35%
or 40%
Ischaemic,12 29 II-IV
Laufs U. et al.[47] 51 NR CHF with NICM Non-ischaemic 42 II-III
Liu M. et al. [48] 67 94 NYHA II-III, CHF with IDCM Ischaemic/ Non-ischaemic 20 II-IV
Mozaffarian D.et al. [49] 51 86 Ambulatory HF, LVEF < 40% Ischaemic, 9 31 II-III
Node K. et al. [50] 54 69 HF with IDCM Non-ischaemic 33 II-III
Sola S. et al. [51] 54 63 Stable non-ischaemic HF Non-ischaemic 33 II-IV
Strey CH. et al. [52] 61 70 Symptomatic HF, LVEF < 40% Non-ischaemic 30 II-III
Takano H. et al.[31] 63 81 CHF, LVEF 45% Ischaemic, 27 34 II-III
Tousoulis D.et al.[29] 69 100 Ischaemic HF, LVEF 35% Ischaemic 25 III-IV
Tousoulis D.et al.[30] 58 NR Stable HF. LVEF 35% Ischaemic, 65.7 25 II-IV
Vrtovec B. et al. [53] 67 54 Stable HF, LVEF < 30% Ischaemic, 62 25 III
Vrtovec B. et al. [54] 62 61 Stable HF, LVEF < 30% Ischaemic, 59 25 III
Wojnicz R. et al. [55] 38 81 Stable HF with DC Non-Ischaemic 28 II-III
Xie RQ. et al.[56] NR NR Ischaemic HF, LVEF<45% Ischaemic,100 38 II-IV
Yamada T. et al.[57] 64 79 Stable HF, NYHA I-III Ischaemic, 53 34 I-III
AMI: acute myocardial infarction; CHF: Chronic Heart Failure; DC: dilated cardiomyopathy; DCM: dilated cardiomyopathy; HF: heart failure; IDCM:
idiopathic dilated cardiomyopathy; LVEF: Left Ventricular Ejection Fraction; NICM: Non-Ischaemic Cardiomyopathy; NR: not reported; NYHA: New York
Heart Association; PCI: percutaneous coronary intervention.
doi:10.1371/journal.pone.0171168.t002
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a concern for all outcomes and this resulted in moderate evidence. Due to missing data or
absence of events, only 8 studies for SCD, 13 studies for all-cause mortality and 12 studies for
HWHF were analyzed.
Efficacy of statins and synthesis of results
We pooled the studies to evaluate effects of statins on the reduction of sudden cardiac death
(SCD), all-cause mortality, and hospitalization due to worsening heart failure (HWHF). The
forest plots in Fig 4 shows insignificant reduction in SCD [Risk Ratio (RR) 0.92; 95% CI, 0.70
to 1.21, P = 0.554] and all-cause mortality [RR 0.88; 95% CI, 0.75 to 1.02, P = 0.092] and a sta-
tistically significant difference in HWHF [RR 0.79; 95% CI, 0.66 to 0.84, P = 0.008]. Random-
effects and fixed-effect models were used to quantify the summary statistic by RR. The effect
Fig 2. Risk of bias for included studies. A) Risk of bias graph for statin trials in heart failure patients: review
authors’ judgments about each risk of bias item presented as percentages across all included studies. B) Risk
of bias summary for statins in heart failure patients: review authors’ judgments about each risk of bias item for
each included study.
doi:10.1371/journal.pone.0171168.g002
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size of fixed-effects models was quite similar to CORONA [13] which weighted 59.9%, 50.8%,
and 63.7% for the respective outcomes of the study population.
In Grade output (Fig 3), the SCD rate was 10.7% (n = 540/5057) in those treated with statins
compared with 10.8% (n = 544/5020) in those treated with placebo/control with an absolute effect
of 9 fewer per 1000 (from 33 fewer to 23 more). All-cause mortality rate was 25.9% (n = 1436/
5549) in those treated with statins compared with 27.3% (n = 1494/5475) in those treated with
placebo/control with an absolute effect of 33 fewer per 1000 (from 68 fewer to 5 more). Also, hos-
pitalization rate was 33.33% (n = 1804/5412) in those treated with statins compared with 38%
(n = 2033/5349) in those treated with an absolute effect of 80 fewer per 1000 (from 23 fewer to
129 fewer) (see also S1 Table). The estimated sample size needed to detect a statistically significant
difference, given the effect size found, were 599506, 15394 and 1642 respectively for SCD, all-
cause mortality and HWHF [59]. Moreover, the estimated predictive intervals (PIs) were statisti-
cally insignificant [0.52 to 1.63, 0.54 to 1.15, and 0.64 to 1.19] in SCD, all-cause mortality and
HWHF, respectively, as shown in Fig 4.
The retrieved published systematic reviews and meta-analyses were evaluated against
potential biases and are compared with the results of our systematic review in the discussion
section.
Meta-regression and heterogeneity of combined studies
For SCD, all-cause mortality and HWHF, heterogeneity estimators were, respectively: I2 =
(42.8%, 37.9%, and 58%) and Tau2 = (0.0353, 0.0135, and 0.0215). We intended to explain the
heterogeneity by a meta-regression analysis for cholesterol levels changes for each outcome
but this was not statistically feasible because of zero events in the intervention or control group
in some trials [log (OR) or log (RR) became undefined]. Also, at least because the number of
studies left for any outcome assessment decreased and the risk of type error may have proba-
bly increased.
However, we tried to explain the heterogeneity observed for assessed outcomes by stratifica-
tion according to follow-up duration. As shown in Fig 5, studies were classified into three cate-
gories: 6 months or less, more than 6 months and less than 12, and more than 12 months.
Negative result was maintained in this analysis except for studies of less than 12 months of fol-
low-up which was likely due to small-study effects, revealed by insignificant reduction for
studies more than 12 months which represented between 85–92% of the studied population.
Fig 3. GRADE summary of findings table.
doi:10.1371/journal.pone.0171168.g003
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Sensitivity and subgroup analyses
Both CORONA [13] and GISSI-HF [12] comprised at least 70% of the study population irrespec-
tive of the outcome or the model used. Therefore, we conducted a sensitivity analysis to assess
the impact of these trials on the results by excluding them from the random-effect estimate. This
resulted into significant difference: RR for SCD [0.27 (95% CI, 0.11 to 0.66), P = 0.004], RR for
all-cause mortality [0.55 (95% CI, 0.40 to 0.77), P = 0.0001], and RR for HWHF [0.54 (95% CI,
0.39 to 0.76), P = 0.0001] (see Fig 6).
Fig 4. Efficacy of statins compared with control in heart failure for the prevention of (A) sudden
cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g004
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On the other hand, after deleting less powered studies, i.e., those with less than 100 patients
in each group, this resulted into insignificant increase in SCD [RR 1.03 (95% CI, 0.88 to 1.20),
P = 0.725], RR for all-cause mortality [0.98 (95% CI, 0.90 to 1.06), P = 0.566], and RR for
HWHF [0.90 (95% CI, 0.79 to 1.04), P = 0.149]. The remaining studies were (CORONA [13],
GISSI-HF [12] for SCD plus Takano H. et al. (PEARL) [31] for all-cause mortality and HWHF
outcomes) (see Figs 7 and 8).
Fig 5. Efficacy of statins compared with control in heart failure stratified by follow-up duration for the
prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening
heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g005
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To test our choice of the summary statistic, we shifted to OR instead of RR, the result
changed slightly: OR for SCD [0.89 (95% CI, 0.65–1.23), P = 0.49], OR for all-cause mortality
[0.81 (95% CI, 0.65–1.00), P = 0.05] and OR for HWHF [0.66 (95% CI, 0.50 to 0.87), P = 0.008].
Also, we stratified studies according to being ischaemic, non-ischaemic or both (see Fig 9). This
resulted into statistically insignificant difference for all outcomes: SCD, all-cause mortality and
HWHF. The effect size for ischaemic group, non-ischaemic and ischaemic/non-ischaemic
were, respectively: SCD [RR 0.42 (95% CI, 0.12–1.47), 0.33 (95% CI, 0.02–7.24), and 0.85 (95%
Fig 6. Sensitivity analysis without corona and GISSI-HF.
doi:10.1371/journal.pone.0171168.g006
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CI, 0.36–1.99), overall P = 0.49]; all-cause mortality [RR 0.68 (95% CI, 0.44–1.05), 0.80 (95% CI,
0.24–2.68), and 0.57 (95% CI, 0.24–1.34), overall P = 0.087]; HWHF [RR 0.97 (95% CI, 0.86–
1.09), 0.53 (95% CI, 0.19–1.49), and 0.57 (95% CI, 0.28–1.17), overall P = 0.015]. We noticed
that only five studies had our outcome of interest as a primary endpoint. When studies were
stratified according to their respective endpoints, this resulted into significant differences and a
considerable heterogeneity among studies with mortality and/or hospitalization endpoints (Fig
10).
Fig 7. Sensitivity analysis without less powered studies.
doi:10.1371/journal.pone.0171168.g007
Statins for sudden cardiac death prevention in heart failure
PLOS ONE | DOI:10.1371/journal.pone.0171168 February 6, 2017 12 / 24
Publication bias
According to the funnel plots, we estimated that publication bias was likely for the three out-
comes (SCD, all-cause mortality, and HWHF); asymmetry appeared bigger for all-cause mor-
tality (Fig 11). Funnel plot analyses were reinforced [60] for all-cause mortality and HWHF
(for which the number of trials was above 10) by Egger and Harbord tests which showed sig-
nificant small-study effects for all-cause mortality (P = 0.001) but insignificant result for
Fig 8. Efficacy of statins compared with control in heart failure stratified by sample size (more than
100 or less than 100) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C)
hospitalization for worsening heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g008
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HWHF (P = 0.088 and P = 0.062). Overall, publication bias was taken into account in the
GRADE evaluation and the synthesis of the study results.
Discussion
Our systematic review and meta-analysis showed no clinical benefits of adding statins to the
treatment of HF patients with reduced left ventricular ejection fraction. Statins are ineffective
Fig 9. Efficacy of statins compared with control in heart failure stratified by population type
(ischaemic or non-ischaemic) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause
mortality, and (C) hospitalization for worsening heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g009
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for the prevention of sudden cardiac death (SCD), all-cause mortality but may slightly decrease
hospitalization for worsening heart failure (HWHF). However, the apparent reduction of HWHF
might result from small-study effects. Actually the studies with a longer follow-up (more than
one year), represented almost 85% of the population in this analysis, showed insignificant reduc-
tion. The little reduction in the number of hospitalization is not supported by the estimated pre-
dictive intervals [0.64 to 1.19] derived from random effects models.
Fig 10. Efficacy of statins compared with control in heart failure stratified by endpoint (those with
against without mortality and/or HWHF) for the prevention of (A) sudden cardiac death (SCD) (B) all-
cause mortality, and (C) hospitalization for worsening heart failure (HWHF). [Random-effects model].
doi:10.1371/journal.pone.0171168.g010
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Several previously published meta-analyses [9,11,18,38] evaluated the effects of statins in
SCD prevention and reported a decrease but all studies were limited by indirectness as they
included different populations, i.e. patient with coronary heart disease (CHD), recent and his-
tory of myocardial infarction (MI), or diabetes, and even primary-and-secondary prevention
statin trials [18].
Another meta-analysis [24] claimed that statins reduce all-cause mortality in chronic heart
failure. The study had a biased result as authors lumped together randomized clinical trials
(RCTs) with non-causal observational studies [61] with a high heterogeneity (I2 = 90%).
Our sensitivity and subgroup analyses suggested a potential publication bias, as indicated by
the unbalanced presence of small studies which showed beneficial effects and heterogeneity
Fig 11. Funnel plots of SE (log odds ratio) by odds ratio to evaluate publication bias for the effect of
treatment for prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization
for worsening heart failure (HWHF). (Fixed-effects model).
doi:10.1371/journal.pone.0171168.g011
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among included studies. The two large clinical trials CORONA [13] and GISSI-HF [12] showed
no benefit of statins and thus different results than the small studies. Many argued that CORONA
[13] and GISSI-HF [12] used a hydrophilic statin (rosuvastatin) that may have a different effec-
tiveness than the predominantly lipophilic statins (atorvastatin, simvastatin, lovastatin, fluvasta-
tin, cerivastatin and pitavastatin)—pravastatin and rosuvastatin are relatively hydrophilic[62].
Fig 12. Efficacy of statins compared with control in heart failure stratified by statin type (lipophilic
versus hydrophilic) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C)
hospitalization for worsening heart failure (HWHF).
doi:10.1371/journal.pone.0171168.g012
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Based on statin type, two meta-analyses [17,21] included lipophilic statins and stated that
they decreased all-cause mortality, cardiovascular death and HWHF. Both studies included
only 13 RCTs, compared to 24 in this analysis, and the latter mistakenly reported death events
in Hammad A. et al. [44] and Node K. et al [50] whereas the authors of those small trials stated
that no death occurred during the study period. This limitation created more small-scale trials
that exaggerated the benefits of lipophilic statins In addition, those meta-analyses included
Takano H. et al. [31], representing at least 48% of the population in the analysis, which used a
lipophilic statin (pitavastatin) and reported no overall significant decrease in all-cause death or
HWHF.
Moreover, a meta-analysis [63] pooled 10 trials (out of the 24 in our analysis) and showed no
benefits for overall non stratified population and concluded for trend toward benefits for ator-
vastatin at subgroup analysis. However, given the influence of small, poor quality RCTs on the
overall pooled results and only 5% of the studied population for atorvastatin, the authors’ con-
clusion seemed overstated [64]. Such result was quite similar to a study [22] which excluded
both CORONA [13] and GISSI-HF [12] for no apparent reason.
Although one cannot exclude that different statins would have different effects on HF out-
comes, the hypothesis of differences among statins does not seem to be biologically plausible
[16]. According to our sensitivity analysis, the inclusion or exclusion of CORONA [13] and
GISSI-HF [12] impacted the result and changed it significantly. Also, since both studies repre-
sented 80% of the population in the analysis, we believe that only large RCTs with head-to-
head comparison would give us reliable evidence (see Fig 12). Of note, two studies [36,39]
directly compared atorvastatin (lipophilic statin) to rosuvastatin (hydrophilic statin) but for
surrogate endpoints like C-reactive protein and hence did not evaluate any clinical outcomes
with a similar output to Lei Zhang et al. [35,37].
On the other hand, a meta-analysis [33] evaluated statins’ effect in mortality prevention in
heart failure with preserved ejection fraction (HFpEF) but included only cohorts and other
observational studies. Our study, restricted to RCTs, did not include these patients. Similarly, a
study [34] reported statin benefits in non-ischaemic cardiomyopathy and included two obser-
vational studies and ad-hoc analysis of 4 RCTs of which 2 were beta-blockers’ trials and so are
not immune to bias. Although our analysis included 7 non-ischaemic HF trials, we could not
pool them all together because of the limited data on mortality events.
A recent systematic review [19] concluded that statins did not decrease mortality, and
might lead to little or no decrease in HWHF which is consistent with our findings. Likewise, a
meta-analysis [20], included 13 trials, among the 24 trials in our analysis, concluded that stat-
ins might have no beneficial effects on all-cause death, cardiovascular death or pump failure
and rehospitalization for heart failure in the overall (non-stratified) CHF populations. The
authors stratified CHF patients according to age but since individual data were not used, the
possible benefits for younger patients (< 65 years) might be unreliable as this could also be
related to the stage and severity of CHF.
Of note, we think that the inability to prove the benefits of statins may be outweighed by a
negative impact of cholesterol lowering in chronic heart failure (CHF) patients, as some evi-
dence suggests that low levels of total cholesterol are associated with worse outcomes and a
marked increase in mortality in CHF.[22,65–67]. Also any harm for statins in HF might also
be masked, given the potential publication bias.
Overall, our updated review supports the current guidelines and do not recommend statins
in patients with diagnosis of heart failure as this will avoid unnecessary prescriptions, overuse
of care, and might help reluctant or hesitating physicians to make an evidence-based decision
based on updated knowledge.
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Limitations and strength of this study
One principle of a meta-analysis is that included studies should be as much as similar to each
other as possible. However, it is almost impossible to find identical studies with the same
patient characteristics. This limitation is common and particularly in heart failure (HF)
patients who usually have various characteristics and co-morbidities.
Our study revealed a potential for publication bias as shown from funnel plots for clinical
outcomes. Although, this might be a serious limitation, we tried to take it into account in the
study synthesis. As a consequence, this limitation had also downgraded the quality of the evi-
dence from high to moderate within GRADE approach.
Our study had no access to individual data and unpublished studies and no data received
by correspondence, though we have contacted studies’ corresponding authors.
For SCD outcome, for instance, due to the limited number of studies in ischaemic and non-
ischaemic groups and potential heterogeneity, we could not investigate if statins have the same
effects on ischaemic and non-ischaemic heart failure.
For blinding of investigators or outcome assessors in included trials, most studies had
unclear risk but we believe this might have little impact due to weak subjectivity at least for
all-cause mortality outcome in double blind trials.
The studies, in our analysis, had not recruited HF patients with preserved ejection fraction
(HFpEF) and so this result might not be applicable to them.
Our study could contribute to the understanding of the existing discordant evidence in
the evaluation of statins efficacy in clinical outcomes in heart failure with reduced ejection
fraction which is revealed by heterogeneity, publication bias and small-study effects within
clinical trials.
To our knowledge, this is the first analysis that evaluates the efficacy of statins for SCD pre-
vention in HF patients; it helps bridge the gap of controversy towards statin benefits in impor-
tant clinical outcomes rather than surrogate endpoints.
Ongoing studies and perspectives
An ongoing study [https://clinicaltrials.gov/ct2/show/NCT01554592] is expected to resolve the
issue of statin withdrawal in CHF patients. Future RCTs are still needed to: (i) compare lipo-
philic statins with hydrophilic statins. (ii) verify any class effect for statins and (iii) if any sub-
population of heart failure might benefit from statins in order to improve survival and reduce
morbidity.
Conclusion
Limited by a potential publication bias, and heterogeneity between studies, our systematic
review and meta-analysis showed that statins do not decrease SCD or all-cause mortality. The
benefits of statins regarding a possible decrease in hospitalization for worsening heart failure
was not supported by estimated predictive intervals which means the expected treatment
effects for a new brand trial. Physicians should follow the current guidelines of ACCF/AHA
and not systematically prescribe statins for heart failure patients with left ventricular ejection
fraction less than 45%. Ongoing and future trials should shed more light if any subpopulation
might benefit from a particular statin.
Summary for current knowledge
Heart failure has a high morbidity and mortality rate despite significant advances in therapy,
diagnosis and management.
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There is some evidence that low total cholesterol is associated with worse outcomes in
(advanced) chronic heart failure, contrary to the general population.
Statin effects in sudden cardiac death prevention in heart failure is unknown and current
discordant studies for other clinical outcomes like all-cause mortality are unresolved.
Summary for this study outcome
This study delivers a clear message of no benefits of statins in HF patients in response to an
existing controversy.
Publication bias and small-study effects offer a possible explanation to the observed discrep-
ancies between trials, and between previous and our meta-analyses.
Within available data and potential publication bias, statins are ineffective in sudden car-
diac death prevention and all-cause mortality reduction and may or may not slightly reduce
hospitalization for worsening heart failure.
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